Back to Report Store Home

Neurodegenerative Disorders Drug Development Pipeline Review, 2017

  • Published: Mar-2017
  • Report Code: GBIHC006IDB
  • Report Format: pdf

Description

List of Figures

Number of Products under Development for Alzheimer's Disease

Number of Products under Development for Alzheimer's Disease – Comparative Analysis

Number of Products under Development for Amyotrophic Lateral Sclerosis

Number of Products under Development for Amyotrophic Lateral Sclerosis – Comparative Analysis

Number of Products under Development for Huntington Disease

Number of Products under Development for Huntington Disease – Comparative Analysis

Number of Products under Development for Multiple Sclerosis

Number of Products under Development for Multiple Sclerosis – Comparative Analysis

Number of Products under Development for Parkinson's Disease

Number of Products under Development for Parkinson's Disease – Comparative Analysis

Number of Products under Development by Companies, Alzheimer's Disease

Number of Products under Development by Companies, Amyotrophic Lateral Sclerosis

Number of Products under Development by Companies, Huntington Disease

Number of Products under Development by Companies, Multiple Sclerosis

Number of Products under Development by Companies, Parkinson's Disease

Number of Products under Investigation by Universities/Institutes, Alzheimer's Disease

Number of Products under Investigation by Universities/Institutes, Amyotrophic Lateral Sclerosis

Number of Products under Investigation by Universities/Institutes, Huntington Disease

Number of Products under Investigation by Universities/Institutes, Multiple Sclerosis

Number of Products under Investigation by Universities/Institutes, Parkinson's Disease

Comparative Analysis by Late Stage Development, Alzheimer's Disease

Comparative Analysis by Clinical Stage Development, Alzheimer's Disease

Comparative Analysis by Early Stage Products, Alzheimer's Disease

Comparative Analysis by Late Stage Development, Amyotrophic Lateral Sclerosis

Comparative Analysis by Clinical Stage Development, Amyotrophic Lateral Sclerosis

Comparative Analysis by Early Stage Products, Amyotrophic Lateral Sclerosis

Comparative Analysis by Late Stage Development, Huntington Disease

Comparative Analysis by Clinical Stage Development, Huntington Disease

Comparative Analysis by Early Stage Products, Huntington Disease

Comparative Analysis by Late Stage Development, Multiple Sclerosis

Comparative Analysis by Clinical Stage Development, Multiple Sclerosis

Comparative Analysis by Early Stage Products, Multiple Sclerosis

Comparative Analysis by Late Stage Development, Parkinson's Disease

Comparative Analysis by Clinical Stage Development, Parkinson's Disease

Comparative Analysis by Early Stage Products, Parkinson's Disease

Comparative Analysis by Unknown Stage Development, Parkinson's Disease

Assessment by Monotherapy Products, Alzheimer's Disease

Assessment by Combination Products, Alzheimer's Disease

Number of Products by Top 10 Targets, Alzheimer's Disease

Number of Products by Stage and Top 10 Targets, Alzheimer's Disease

Number of Products by Top 10 Mechanism of Actions, Alzheimer's Disease

Number of Products by Stage and Top 10 Mechanism of Actions, Alzheimer's Disease

Number of Products by Top 10 Routes of Administration, Alzheimer's Disease

Number of Products by Stage and Top 10 Routes of Administration, Alzheimer's Disease

Number of Products by Top 10 Molecule Types, Alzheimer's Disease

Number of Products by Stage and Top 10 Molecule Types, Alzheimer's Disease

Assessment by Monotherapy Products, Amyotrophic Lateral Sclerosis

Assessment by Combination Products, Amyotrophic Lateral Sclerosis

Number of Products by Top 10 Targets, Amyotrophic Lateral Sclerosis

Number of Products by Stage and Top 10 Targets, Amyotrophic Lateral Sclerosis

Number of Products by Top 10 Mechanism of Actions, Amyotrophic Lateral Sclerosis

Number of Products by Stage and Top 10 Mechanism of Actions, Amyotrophic Lateral Sclerosis

Number of Products by Top 10 Routes of Administration, Amyotrophic Lateral Sclerosis

Number of Products by Stage and Top 10 Routes of Administration, Amyotrophic Lateral Sclerosis

Number of Products by Top 10 Molecule Types, Amyotrophic Lateral Sclerosis

Number of Products by Stage and Top 10 Molecule Types, Amyotrophic Lateral Sclerosis

Assessment by Monotherapy Products, Huntington Disease

Number of Products by Top 10 Targets, Huntington Disease

Number of Products by Stage and Top 10 Targets, Huntington Disease

Number of Products by Top 10 Mechanism of Actions, Huntington Disease

Number of Products by Stage and Top 10 Mechanism of Actions, Huntington Disease

Number of Products by Top 10 Routes of Administration, Huntington Disease

Number of Products by Stage and Top 10 Routes of Administration, Huntington Disease

Number of Products by Top 10 Molecule Types, Huntington Disease

Number of Products by Stage and Top 10 Molecule Types, Huntington Disease

Assessment by Monotherapy Products, Multiple Sclerosis

Number of Products by Top 10 Targets, Multiple Sclerosis

Number of Products by Stage and Top 10 Targets, Multiple Sclerosis

Number of Products by Top 10 Mechanism of Actions, Multiple Sclerosis

Number of Products by Stage and Top 10 Mechanism of Actions, Multiple Sclerosis

Number of Products by Top 10 Routes of Administration, Multiple Sclerosis

Number of Products by Stage and Top 10 Routes of Administration, Multiple Sclerosis

Number of Products by Top 10 Molecule Types, Multiple Sclerosis

Number of Products by Stage and Top 10 Molecule Types, Multiple Sclerosis

Assessment by Monotherapy Products, Parkinson's Disease

Assessment by Combination Products, Parkinson's Disease

Number of Products by Top 10 Targets, Parkinson's Disease

Number of Products by Stage and Top 10 Targets, Parkinson's Disease

Number of Products by Top 10 Mechanism of Actions, Parkinson's Disease

Number of Products by Stage and Top 10 Mechanism of Actions, Parkinson's Disease

Number of Products by Top 10 Routes of Administration, Parkinson's Disease

Number of Products by Stage and Top 10 Routes of Administration, Parkinson's Disease

Number of Products by Top 10 Molecule Types, Parkinson's Disease

Number of Products by Stage and Top 10 Molecule Types, Parkinson's Disease

 
      captcha refresh

I have read and accept terms and conditions and privacy policy

Cancel
License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$3995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$7990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$11985
Email to a colleague Request Sample Pages Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5817
Or click here to contact us
Secure Payments
Cards